Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
VP4896
- Development stage
- Unknown
- Lead developer
- Voyager Therapeutics
- Modality
- Implantable Devices → Device-based Delivery → Drug Delivery Systems
- Administration
- Implant
01
Overview
VP4896 is a proprietary, small, biodegradable implant developed by Voyager Pharmaceutical Corporation. It contains leuprolide acetate and a polymer. It was designed as a potential treatment for mild-to-moderate Alzheimer's disease based on the hypothesis that luteinizing hormone may contribute to disease development. VP4896 works as a gonadotropin-releasing hormone (GnRH) agonist that binds to and inactivates GnRH receptors on the pituitary gland, aiming to decrease the amount of luteinizing hormone released. Voyager Pharmaceutical Corporation conducted Phase III clinical trials for VP4896, including the ALADDIN Study, to assess its safety and efficacy in treating subjects with mild-to-moderate Alzheimer's disease. Primary efficacy endpoints included changes in ADAS-Cog and ADCS-CGIC scores. Pooled analysis from two studies reportedly showed significant improvement after 48 weeks.
- Other names
- leuprolide acetate implantleuprorelin acetate
02
Targets
GnRHR (Gonadotropin-releasing hormone receptor)
Beyond the preview
Go deeper on VP4896.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VP4896.